Embecta Acquires Owen Mumford for £150 Million to Expand Drug Delivery Platform Capabilities
Key Insights
Embecta Corp. has entered into a definitive agreement to acquire UK-based medical device innovator Owen Mumford Holdings Limited (search) for up to £150 million, including £100 million upfront and up to £50 million in performance-based payments.
The acquisition will expand Embecta's reach into drug delivery devices supporting therapies across obesity (search), autoimmune diseases (search), and anaphylaxis (search), leveraging Owen Mumford's Aidaptus (search) auto-injector platform.
Owen Mumford generated approximately £69.4 million in revenue in fiscal year 2025, with 80% of sales from the UK and United States.
Embecta Corp., a global leader in diabetes (search) care technology, announced it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited (search), a UK-based medical device innovator, for up to £150 million. The transaction includes an upfront cash payment of £100 million at closing and up to £50 million in performance-based payments tied to net sales of the Aidaptus (search) auto-injector platform over three years following closing.
The acquisition, unanimously approved by Embecta's board of directors, is expected to close in the company's fiscal third quarter of 2026, subject to regulatory approvals and customary closing conditions.
Strategic Expansion into Drug Delivery
Owen Mumford brings expertise in drug delivery platforms and medical device technologies, with a portfolio spanning autoinjectors, point-of-care diagnostics, self-injection devices, and pelvic health solutions. The company generated approximately £69.4 million in revenue in fiscal year 2025, with around 80% of its sales coming from the UK and the United States.
"We are extremely pleased to announce this agreement to acquire Owen Mumford, a company that has earned a global reputation for innovation, quality and patient-centered design," said Devdatt (Dev) Kurdikar, Chairman, President and CEO of Embecta. "This acquisition is expected to sustainably improve embecta's revenue growth trajectory and will accelerate our strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients in the obesity (search), diabetes (search), autoimmune diseases (search) and anaphylaxis (search) markets."
Aidaptus Platform Central to Growth Strategy
The acquisition is designed to accelerate Embecta's transformation into a broader medical supplies company while expanding its reach into drug delivery devices supporting therapies across multiple areas, including obesity (search), autoimmune diseases (search), and anaphylaxis (search). Owen Mumford's Aidaptus (search) auto-injector platform is expected to play a central role, offering a streamlined manufacturing process and scalable design intended to support pharmaceutical partners.
Owen Mumford pioneered the first plastic autoinjector and has continued to innovate and expand their product portfolio, specializing in the design and manufacture of drug delivery devices. The Aidaptus (search) platform combines an innovative patient-centric design and novel technology with one form factor and a single final assembly process, streamlining large-scale manufacturing while reducing changeovers and supply chain complexity.
Global Commercial Leverage
Embecta expects to leverage its global commercial infrastructure, which spans more than 100 countries, to expand Owen Mumford's geographic reach and scale its product portfolio. The combined capabilities are anticipated to enhance manufacturing efficiencies by integrating Owen Mumford's device design and assembly expertise with Embecta's high-volume production capabilities.
"Owen Mumford has a 70-year track-record of developing innovative solutions with long-term growth potential," said Gavin Jones, Managing Director of Owen Mumford. "With our complementary portfolios and manufacturing expertise, and by leveraging embecta's commercial scale, we will continue to drive innovation that improves the quality of life for people living with chronic conditions and other healthcare needs while creating new opportunities for our valued customers and the Owen Mumford team."
Financial Projections and Financing
From a financial perspective, Embecta expects the acquisition to contribute to revenue growth beginning in fiscal year 2027. The deal is projected to be dilutive to adjusted net income in fiscal 2027, neutral in fiscal 2028, and accretive thereafter. The company also anticipates generating a high-single-digit return on invested capital by the fourth year following closing, with increasing contributions over time.
To finance the transaction, Embecta plans to utilize borrowings under its revolving credit facility while maintaining a long-term commitment to reducing debt and strengthening financial flexibility. The company will provide additional details about the acquisition during its fiscal second quarter 2026 earnings call scheduled for May 5, 2026.